Press releaseGlobe Newswire
Pelthos Therapeutics
PTHS · NYSE American
$20.50+$0.24 (+1.18%)TodayMarket closed ·
Prev close $20.26
About PTHS
- Employees
- 92
- Headquarters
- Durham, North Carolina
- Listed
- Feb 16, 2024
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- ir.pelthos.com
PTHS key statistics
- Market cap
- 78.48M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 41.12K
- Volume
- 75.95K
- Open price
- $20.12
- High today
- $20.75
- Low today
- $20.12
- 52 Week high
- $37.50
- 52 Week low
- $18.19
Pelthos Therapeutics (PTHS) at a glance
Pelthos Therapeutics (PTHS) last traded at $20.50, with a market cap of 78.48M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $20.12 and $20.75. The current price is 1.9% above the day's low and 1.2% below its high.
Volume so far is 75.95K shares, above the average of 41.12K shares a day.
Over the past year Pelthos Therapeutics has ranged from $18.19 to $37.50, and now sits 12% of the way up that range.
Pelthos Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$5.13 per share against an estimate of -$3.11.
The average analyst price target is $54.21, 164.4% above the current price, from 6 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
100%of 6 analyst ratings say Buy
- Buy100.0%
- Hold0.0%
- Sell0.0%
Price target · 9 analystsAvg $54.21
- Low
- $45.45
- Now
- $20.50
- High
- $67.20
PTHS earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 3 of the last 8 quarters, by 25.0% on average.
- Q2 FY24: reported -$3.10 per share against an estimate of -$2.96
- Q3 FY24: reported -$2.90 per share against an estimate of -$2.35
- Q4 FY24: reported -$3.20 per share against an estimate of -$2.14
- Q2 FY25: reported -$5.38 per share against an estimate of -$6.39
- Q3 FY25: reported -$5.30 per share against an estimate of -$0.4386
- Q4 FY25: reported -$2.03 per share against an estimate of -$4.21
- Q1 FY26: reported -$3.09 per share against an estimate of -$3.34
- Q2 FY26: reported -$5.13 per share against an estimate of -$3.11
PTHS news
- Press releaseGlobe Newswire
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Press releaseBusiness Wire
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
- Press releaseGlobe Newswire
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
- Press releaseGlobe Newswire
Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results
- Vandana Singh
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
Similar companies
Companies in the same industry as Pelthos Therapeutics
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.